Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis

References

• Carrascosa JM, Jacobs I, Petersel D, et al. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther. 2018;8(2):173–194.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration [Internet]. Purple Book Database of Licensed Biological Products. Silver Spring (MD): USFDA; 2021 [cited 2021 Nov 1]. Available from: https://purplebooksearch.fda.gov.
   Google Scholar
• Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939.
   PubMed Web of Science ®Google Scholar
• Kirchhoff CF, Wang XM, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–2705.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration [Internet]. Scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring (MD): USFDA; 2015 [2021 Nov 1]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product.
   Google Scholar
• Declerck P, Farouk Rezk M. The road from development to approval: evaluating the body of evidence to confirm biosimilarity. Rheumatology. 2017;56(4):iv4–iv13.
   PubMedGoogle Scholar
• Puig L, López-Ferrer A. Biosimilars for the treatment of psoriasis. Expert Opin Biol Ther. 2019;19(10):993–1000.
   PubMed Web of Science ®Google Scholar
• Barbier L, Ebbers HC, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–755.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–938.
   PubMed Web of Science ®Google Scholar
• Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the nor-SWITCH trial. J Intern Med. 2019;285(6):653–669.
   PubMed Web of Science ®Google Scholar
• Nielsen VW, Lund TT, Gniadecki R, et al. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e14258.
   PubMed Web of Science ®Google Scholar
• Giunta A, Zangrilli A, Bavetta M, et al. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator. Curr Med Res Opin. 2021;37(7):1099–1102.
   PubMed Web of Science ®Google Scholar
• Gallo G, Rostagno E, Siliquini N, et al. Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: a real-life experience in a tertiary referral Centre. Australas J Dermatol. 2021;62(3):e431–e432.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Tronconi G, Fastame TM, et al. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2020;33(3):e13435.
   PubMed Web of Science ®Google Scholar
• Loft N, Egeberg A, Rasmussen MK, et al. Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676–683.
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Lazzeri L, Di Cesare A, et al. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients. Int J Clin Pharm. 2019;41(1):9–12.
   PubMed Web of Science ®Google Scholar
• Lund T, Sand C, Gniadecki R, et al. Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis. Dermatol Ther. 2019;32(3):e12846.
   PubMed Web of Science ®Google Scholar
• Giunta A, Manfreda V, Esposito M, et al. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study. Br J Dermatol. 2019;181(5):1078–1079.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bianchi L, Calzavara-Pinton P, et al. Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars Registry. Br J Dermatol. 2019;180(2):409–410.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Conti A, Messina F, et al. Cross-switch from etanercept originator to biosimilar SB4 and to GP2015 in patients with chronic plaque psoriasis. BioDrugs. 2021;35(4):469–471.
   PubMed Web of Science ®Google Scholar
• Dapavo P, Vujic I, Fierro MT, et al. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(4):736–739.
   PubMed Web of Science ®Google Scholar
• Ricceri F, Pescitelli L, Lazzeri L, et al. Clinical experience with infliximab biosimilar in psoriasis. Br J Dermatol. 2017;177(6):e347–e348.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bianchi L, Conti A, et al. Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars Registry. Br J Dermatol. 2017;177(6):e325–e326.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Virga C, Piaserico S, et al. Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. Br J Dermatol. 2020;183(2):397–398.
   PubMed Web of Science ®Google Scholar
• Teeple A, Ellis LA, Huff L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35(4):611–617.
   PubMed Web of Science ®Google Scholar
• Teeple A, Ginsburg S, Howard L, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–609.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Cohen AD, Puig L, et al. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. Br J Dermatol. 2016;174(2):282–286.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Alten R, Puig L, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32(5):397–404.
   PubMed Web of Science ®Google Scholar
• Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol. 2018;14(2):155–161.
   PubMed Web of Science ®Google Scholar